๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Evaluation of cancer screening programs. Parallels with clinical trials

โœ Scribed by Dr. Aristide Apostolides; Maureen Henderson


Publisher
John Wiley and Sons
Year
1977
Tongue
English
Weight
586 KB
Volume
39
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis


The methodologic limitations of available observational evidence for the evaluation of ongoing cancer control programs is reviewed. The specific example of Control Programs for Cervical Cancer is chosen to illustrate these limitations. These limitations pertain to the special features of the natural history of this disease, to the types of data available as well as to problems in the interpretation of these data. Given the unacceptability of conducting a rigorous randomized clinical trial of an ongoing and accepted cancer control procedure, an alternative experimental approach is proposed. This approach consists in the random allocation of census tracts with a high risk population to either of two groups: 1) an experimental group in which active and repeated screening activities will attempt to reach virtually all susceptible women, 2) a comparable control group which will only benefit from regularly available services.


๐Ÿ“œ SIMILAR VOLUMES


An evaluation of phase I cancer clinical
โœ Chul Ahn ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 88 KB ๐Ÿ‘ 2 views

Phase I clinical trials are designed to identify an appropriate dose for experimentation in phase II and III studies. I present the results from a simulation study to evaluate the performance of nine phase I designs involving the standard design, the two-stage modified Storer's design, the two-stage

Instrumental variables when evaluating s
โœ Martin W. McIntosh ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 261 KB ๐Ÿ‘ 3 views

When evaluating the bene"t of detecting cancer by screening we try to answer the question, &what would a screen detected subject's outcome have been if his/her cancer had progressed to clinical detection'. By &outcome' we mean survival time, cancer size and stage, lead time e!ects and more. Because